New Frontiers in the Treatment of Type 1 Diabetes
Author:
Funder
FDA
Publisher
Elsevier BV
Subject
Cell Biology,Molecular Biology,Physiology
Reference141 articles.
1. Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances;Ahmed;Diabetes,2019
2. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes;Alhadj Ali;Sci. Transl. Med.,2017
3. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study;Ambery;Diabet. Med.,2014
4. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019;Diabetes Care,2019
5. The NOD mouse: a model of immune dysregulation;Anderson;Annu. Rev. Immunol.,2005
Cited by 163 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Long-term Tolerance to Islet Transplantation via Targeted Reduction of beta cell-specific T cells;2024-09-03
2. Rigid crosslinking of the CD3 complex leads to superior T cell stimulation;Frontiers in Immunology;2024-08-30
3. Recent progress in modeling and treating diabetes using stem cell-derived islets;Stem Cells Translational Medicine;2024-08-19
4. Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review;World Journal of Diabetes;2024-08-15
5. Teplizumab’s immunomodulatory effects on pancreatic β-cell function in type 1 diabetes mellitus;Clinical Diabetes and Endocrinology;2024-08-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3